OncotypeDX recurrence score and its relationship with basic immunohistochemistry for breast cancer patients in a Colombian cancer unit.
Fernando Herazo(Instituto de Cancerología Las Américas), Ana M. González-Angulo(The University of Texas MD Anderson Cancer Center), Claudia Ramirez, Mauricio Borrero(Instituto de Cancerología Las Américas), Carlos Andrés Ossa(Instituto de Cancerología Las Américas), Luis Rodolfo Manosalvas Gómez(Amec Foster Wheeler (United States)), Jorge Madrid(Instituto de Cancerología Las Américas), Carolina Echeverri(Instituto de Cancerología Las Américas), Héctor Iván García García(Universidad de Antioquia), Mónica Gil(Instituto de Cancerología Las Américas), Gonzalo Ángel(Instituto de Cancerología Las Américas)
Cited by 0
Related Papers
Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
|Cell Reports|2013|630
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer
|Breast Cancer Research|2010|258
Day care and selected employee work behaviors.
|PubMed|1976|62
cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer
|Journal of Cancer|2014|59
A multi-gene panel study in hereditary breast and ovarian cancer in Colombia
|Familial Cancer|2017|49